ABCL

AbCellera Biologics Inc.

NasdaqGSUSDEQUITY DELAYED

11.31

▼ 0.26 (2.25%)

MARKET · —

Price

Open

11.55

Prev close

11.57

Day high

11.80

Day low

11.14

Volume

4.54M

Market cap

—

P/E (TTM)

—

52W range

2.75 – 12.15

Trailing performance

Price return · vs SPY

Returnvs SPY

-0.53% +0.8%

+99.65% +95.9%

+120.23% +117.1%

+272.37% +261.3%

YTD

+230.99% +218.7%

+171.46% +151.5%

+105.82% +31.6%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

10.90

+3.73% from price

SMA 20

8.38

+35.04% from price

SMA 50

7.21

+57.02% from price

SMA 100

5.88

+92.41% from price

SMA 200

4.76

+137.83% from price

EMA 12

10.23

+10.59% from price

EMA 26

8.76

+29.13% from price

EMA 50

7.59

+48.90% from price

RSI (14)

73.9

Overbought

MACD (12,26,9)

1.47

Hist 0.35

ATR (14)

1.01

8.89% of price

Realised vol 30D

112.4%

Annualised

Bollinger upper

13.60

20, 2σ

Bollinger lower

3.17

20, 2σ

50 / 200 cross

Golden

7.21 vs 4.76

Trend bias

Above 200

+137.83%

Risk profile

Daily returns · 1Y window

Beta vs SPY

2.60

More volatile than market

Correlation to SPY

0.39

Loosely linked

Realised vol 30D

112.4%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-54.9%

Peak to trough

Max drawdown 5Y

-91.0%

Peak to trough

ATR 14

1.01

8.89% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 11.31

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ABCL · links out to the publisher

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity Insider Monkey · 7d ago Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? Insider Monkey · 8d ago Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Producer Inflation Data Release MT Newswires · 9d ago AbCellera Biologics Prices $200 Million Offering of Shares, Pre-Funded Warrants MT Newswires · 9d ago AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants Business Wire · 9d ago AbCellera (ABCL) Q2 2026 Earnings Call Transcript Motley Fool · 10d ago AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed? Simply Wall St. · 10d ago AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal Simply Wall St. · 10d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.